CD274 and non-small cell lung carcinoma: PD-1 inhibitors pembrolizumab (Keytruda) and nivolumab (Opdivo) are used in the treatment of melanoma of the skin, NSCLC, kidney cancer, head and neck squamous cell carcinoma (HNSCC), and Hodgkins lymphoma, while PD-L1 inhibitors such as atezolizumab (Tecentriq) are used in the treatment of bladder cancer [9].